Offerings

ONWARD® Medical Publishes Closing of Accelerated Bookbuild Offering and Public Offering in France

Retrieved on: 
Monday, March 25, 2024
Offerings, Private, Brussels Stock Exchange, Euronext, DSM-IV codes, NOT, Euronext Amsterdam, Movement, SCI, Security (finance)

EINDHOVEN, the Netherlands, March 25, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD) (the “Company” or “ONWARD Medical”), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and movement disorders, announces today the closing of its previously announced private placement with institutional investors, certain founders, certain members of management, and certain members of the Board of Directors (the “Private Placement”) and of its separate public offering via the PrimaryBid platform with retail investors in France (the “Public Offer” and together with the Private Placement the “Offerings”).  The gross proceeds from the Offerings amount to €20 million. 

Key Points: 
  • OTHER RESTRICTIONS ARE APPLICABLE.
  • PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.
  • As of today, the new shares issued pursuant to the Offerings are admitted to listing and trading on Euronext Brussels and Euronext Amsterdam.
  • This press release does not constitute, contain, or form part of an offering of securities in any jurisdiction.

ONWARD® Medical Publishes Prospectus for Listing of New Shares

Retrieved on: 
Thursday, March 21, 2024
EUR, Offerings, AFM, Euronext, Prospectus, DSM-IV codes, Market, NOT, Movement, SCI

EINDHOVEN, the Netherlands, March 21, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD) (the “Company” or “ONWARD Medical”), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and movement disorders, announces today that it has published a prospectus for the admission to listing of 4,444,444 ordinary shares in the Company’s share capital, with a nominal value of EUR 0.12 each, issued through a private placement with institutional investors, certain founders and certain members of management, and certain members of the Board of Directors (the “Private Placement”) and in a separate public offering via the PrimaryBid platform with retail investors in France (the “Public Offer”), for which pricing and allocation have occurred prior to trading on March 21, 2024 (the “Offerings”). In connection with the listing of the shares placed in the Offerings, a listing prospectus was published today. The prospectus was approved by the Netherlands Authority for the Financial Markets (AFM) on March 21, 2024 and can be downloaded via ir.onwd.com/shareholder-information.

Key Points: 
  • PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.
  • In connection with the listing of the shares placed in the Offerings, a listing prospectus was published today.
  • The prospectus was approved by the Netherlands Authority for the Financial Markets (AFM) on March 21, 2024 and can be downloaded via ir.onwd.com/shareholder-information .
  • This press release does not constitute, contain, or form part of an offering of securities in any jurisdiction.

ONWARD® Medical Successfully Raises €20 Million in a Capital Increase by Way of an Accelerated Bookbuild Offering and by Way of a Public Offering in France

Retrieved on: 
Thursday, March 21, 2024
Offerings, Public, Private, Brussels Stock Exchange, KBC, Euronext, DSM-IV codes, CSO, Euronext Amsterdam, NOT, SCI, Movement, Hand, Security (finance)

PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.

Key Points: 
  • PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.
  • “We are delighted to announce the successful capital raise of €20 million, including a fully subscribed upsize option despite challenging market conditions,” said Dave Marver, CEO of ONWARD Medical.
  • Existing shareholders participated in the deal with an aggregate of 333,333 shares and 333,333 shares respectively allocated to INKEF Capital and EQT Life Sciences.
  • Following the Offerings, INKEF Capital and EQT Life Sciences will respectively hold 11.5% and 11.2% of the Company’s share capital.

ONWARD® Medical Launches Capital Increase by Way of an Accelerated Bookbuild Offering and of a Public Offering in France for an Indicative Amount of EUR 15 Million, with an Up to EUR 5 Million Upsize Option

Retrieved on: 
Wednesday, March 20, 2024
Brussels Stock Exchange, SCI, Public, Private, KBC, VWAP, ARC, Hand, Acceleration, Regulation, DSM-IV codes, CSO, Movement, EUR, Private placement, BCI, Offerings, Public offering, Equity carve-out, Euronext, Issue, Euronext Amsterdam, Security (finance)

The final number of New Shares placed and the issue price per New Share (the “Issue Price”) will be announced after pricing of the Offerings.

Key Points: 
  • The final number of New Shares placed and the issue price per New Share (the “Issue Price”) will be announced after pricing of the Offerings.
  • The New Shares will be issued from the Company’s authorized capital under exclusion of the existing shareholders’ pre-emptive rights.
  • “It is the Company’s intention to raise gross proceeds of indicatively EUR 15 million from the Offerings, with an up to EUR 5 million upsize option.
  • A separate announcement will be made shortly regarding the Public Offer in France via the PrimaryBid platform and its terms.

ONWARD® Medical Launches Capital Increase by Way of an Accelerated Bookbuild Offering and of a Public Offering in France for an Indicative Amount of EUR 15 Million, with an Up to EUR 5 Million Upsize Option

Retrieved on: 
Wednesday, March 20, 2024
Failure, Economy, Brussels Stock Exchange, Exercise, Patient, Risk, European, Intellectual property, Marketing, SCI, Annual, Public, Private, KBC, AFM, Prospectus, Royal Victorian Order, VWAP, ARC, Hand, Acceleration, Part, Research, Classification, Enrollment, Certification, DSM-IV codes, CSO, FDA, Movement, Engineering, EUR, Private placement, BCI, Offerings, Public offering, Market, Issue, Euronext Amsterdam, Probability, Security (finance)

The Issue Price will be determined by the accelerated book-building initiated with institutional investors.

Key Points: 
  • The Issue Price will be determined by the accelerated book-building initiated with institutional investors.
  • The Public Offering will not extent to retail investors located outside of France.
  • The New Shares will be issued from the Company’s authorized capital under exclusion of the existing shareholders’ pre-emptive rights.
  • It is the Company’s intention to raise gross proceeds of approximately €15.0 million from the Offerings, with an up to €5 million upsize option.

Indiva Announces Filing of Amended and Restated Offering Document and Concurrent Private Placement of up to $4.3 Million

Retrieved on: 
Wednesday, February 28, 2024
Retail, Specialty, Natural Resources, Cannabis, Offerings, TSX Venture Exchange, Limited, News, Part, Sale, Warrant, Private, Indian stock exchange, National instrument, Legislation, Acceleration, Concurrency, Security (finance)

The LIFE Offering pursuant to the Amended and Restated Offering Document will consist of up to 40,000,000 units of the Company (each, a "LIFE Unit") for aggregate gross proceeds to the Company of up to $4,000,000.

Key Points: 
  • The LIFE Offering pursuant to the Amended and Restated Offering Document will consist of up to 40,000,000 units of the Company (each, a "LIFE Unit") for aggregate gross proceeds to the Company of up to $4,000,000.
  • The Amended and Restated Offering Document relating to the LIFE Offering can be accessed under the Company's profile at www.sedarplus.ca and at www.indiva.com .
  • Prospective investors should read the Amended and Restated Offering Document before making an investment decision.
  • Upon closing of the Concurrent Offering, the Company may pay certain eligible finders a finder's fee of up to $400,000.

Dye & Durham Announces Approximately $126 Million Bought Deal Offering of Common Shares

Retrieved on: 
Wednesday, January 17, 2024
Dye, Offerings, Person, Underwriting, Toronto Stock Exchange, DND, WIRE, Sale, TSX, Offering, NEWS, NOT, Security (finance)

The Company intends to use the net proceeds of the Offerings for the repayment of debt.

Key Points: 
  • The Company intends to use the net proceeds of the Offerings for the repayment of debt.
  • The Offering is consistent with the Company's previously stated goal to delever the business.
  • Following closing of the Offering, the Company will have made significant progress towards its target of reducing its leverage ratio to less than four times total net debt to adjusted EBITDA .
  • No securities regulatory authority has either approved or disapproved the contents of this press release.

CANADA CARBON ANNOUNCES PRIVATE PLACEMENT OF FLOW-THROUGH UNITS AND ORDINARY UNITS

Retrieved on: 
Tuesday, December 5, 2023
Carbon, Offerings, TSX Venture Exchange, Income Tax Act, Indian stock exchange, NOT, Legislation, News, CCB, Person, Unit, TSX, The Company, Concurrency, FT, Security (finance)

Toronto, ON, Canada, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Canada Carbon Inc. (the "Company") (TSX-V : CCB) is pleased to announce a non-brokered private placement of up to 16,666,666 flow-through units (each, a “FT Unit”) at a price of $0.03 per FT Unit for agg­regate gross proceeds of up to $500,000 (the “FT Offering”). Each FT Unit shall be comprised of one (1) flow-through share in the capital of the Company (each, a “FT Share”) and one-half of one (1/2) common share purchase warrant (each, a “Warrant”). Each whole Warrant shall entitle the holder thereof to acquire one common share (each, a “Common Share”) at a price of $0.05 per share for a period of 24 months from the date of issuance. The FT Shares will qualify as “flow-through shares” within the meaning of the Income Tax Act (Canada).

Key Points: 
  • Toronto, ON, Canada, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Canada Carbon Inc. (the "Company") (TSX-V : CCB) is pleased to announce a non-brokered private placement of up to 16,666,666 flow-through units (each, a “FT Unit”) at a price of $0.03 per FT Unit for agg­regate gross proceeds of up to $500,000 (the “FT Offering”).
  • The FT Shares will qualify as “flow-through shares” within the meaning of the Income Tax Act (Canada).
  • In addition to the FT Offering, the Company will be completing a non-brokered private placement of up to 3,333,333 units (each, an “Ordinary Unit”) at a price of $0.03 per Ordinary Unit for aggregate gross proceeds of up to $100,000 (the “Concurrent Offering” and together with the FT Offering, the “Offerings”).
  • Each Ordinary Unit is comprised of one (1) Common Share and one (1) Warrant.

Capital Power announces closing of $400 million subscription receipts offerings

Retrieved on: 
Tuesday, November 28, 2023
Private, Capital Power Corporation, Offerings, Public, Indigenous peoples, Sale, NOT, Risk management, Person, Electricity, WIRE, Bookrunner, Investment, News, Computershare, Perception, Alberta Investment Management Corporation, CSG, TSX, National bank, CPX, CXA, Toronto Stock Exchange, Beal, Capital, Climate, Security (finance)

EDMONTON, Alberta, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Capital Power Corporation (“Capital Power” or the “Company”) (TSX: CPX) announced today that it has completed its previously announced public and private placement offerings of subscription receipts (collectively the “Offerings”). The public offering consisted of the issuance of 8,231,000 subscription receipts (the “Public Subscription Receipts”), on a bought deal basis, at an issue price of $36.45 per Public Subscription Receipt (the “Offering Price”), for total gross proceeds of approximately $300 million (the “Public Offering”) pursuant to an underwriting agreement with a syndicate of underwriters (the “Underwriters”) led by TD Securities Inc. and National Bank Financial Inc. The Company has granted the Underwriters an over-allotment option to purchase, in whole or part, up to an additional 1,234,650 Public Subscription Receipts at the Offering Price to cover over-allotments, if any, exercisable at any time and from time to time until the date that is 30 days following the closing of the Public Offering. If the over-allotment option is exercised in full, gross proceeds from the Public Offering will be approximately $345 million.

Key Points: 
  • NOT FOR DISTRIBUTION TO THE U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
    EDMONTON, Alberta, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Capital Power Corporation (“Capital Power” or the “Company”) (TSX: CPX) announced today that it has completed its previously announced public and private placement offerings of subscription receipts (collectively the “Offerings”).
  • If the over-allotment option is exercised in full, gross proceeds from the Public Offering will be approximately $345 million.
  • Concurrently, the Company issued 2,745,000 subscription receipts (together with the Public Subscription Receipts, the “Subscription Receipts”) at the Offering Price to Alberta Investment Management Corporation (“AIMCo”) on a private placement basis for gross proceeds of approximately $100 million (the “Private Placement”).
  • Each Subscription Receipt will entitle the holder thereof to receive, without payment of additional consideration or further action, upon the first to close of the Acquisitions (as defined below), one common share of Capital Power.

SOTERA ALERT: Bragar Eagel & Squire, P.C. is Investigating Sotera Health Co. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, November 14, 2023
NATA, EPA, Pressure, Safety, Telephone, Poison, Offerings, Warburg Pincus, Risk, Probability, Culture, Agency, SPO, Goldman Sachs, JPMorgan Chase, Class, Health, Human services, SHC, School, IPO, Sterilization, Cancer, Human, Atmosphere, P.C, Ethylene oxide, Knowledge, GTCR, News, Cryptocurrency, Dietary supplement, Environmental remediation, Tobacco, Sotera Tschetter, Nordion

Our investigation concerns whether the board of directors of Sotera have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of Sotera have breached their fiduciary duties to the company.
  • Sotera provides sterilization and lab testing and advisory services to the medical device and pharmaceutical industries.
  • The Company’s sterilization services rely on three primary technologies, one of which is Ethylene Oxide (“EtO”) processing.
  • Sotera, through its Sterigenics business, conducts or has conducted EtO processing at facilities located in Illinois, California, Georgia, and New Mexico.